Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Alnylam Pharmaceuticals stock

Learn how to easily invest in Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,665 staff and has a trailing 12-month revenue of around $960.9 million.

How to buy Alnylam Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – ALNY. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Alnylam Pharmaceuticals stock price (NASDAQ: ALNY)

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals shares at a glance

Information last updated 2023-01-31.
Latest market close$224.91
52-week range$117.58 - $242.97
50-day moving average $227.22
200-day moving average $187.48
Wall St. target price$246.39
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-7.49

Buy Alnylam Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alnylam Pharmaceuticals price performance over time

Historical closes compared with the close of $224.91 from 2023-02-01

1 week (2023-01-27) -2.79%
1 month (2023-01-03) -3.72%
3 months (2022-11-03) 4.26%
6 months (2022-08-03) 6.08%
1 year (2022-01-30) N/A
2 years (2021-02-03) 48.70%
3 years (2020-02-03) 96.15%
5 years (2018-02-02) 80.65%

Alnylam Pharmaceuticals financials

Revenue TTM $960.9 million
Gross profit TTM $704.1 million
Return on assets TTM -14.11%
Return on equity TTM -343.51%
Profit margin -123.02%
Book value $-0.55
Market capitalisation $27.7 billion

TTM: trailing 12 months

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $117.58 up to $242.97. A popular way to gauge a stock's volatility is its "beta".

ALNY.US volatility(beta: 0.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 0.5033. This would suggest that Alnylam Pharmaceuticals's shares are less volatile than average (for this exchange).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Alnylam Pharmaceuticals is owned by insiders or institutions?
Currently 0.523% of Alnylam Pharmaceuticals shares are held by insiders and 97.637% by institutions.
How many people work for Alnylam Pharmaceuticals?
Latest data suggests 1,665 work at Alnylam Pharmaceuticals.
When does the fiscal year end for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's fiscal year ends in December.
Where is Alnylam Pharmaceuticals based?
Alnylam Pharmaceuticals's address is: 675 West Kendall Street, Cambridge, MA, United States, 02142
What is Alnylam Pharmaceuticals's ISIN number?
Alnylam Pharmaceuticals's international securities identification number is: US02043Q1076
What is Alnylam Pharmaceuticals's CUSIP number?
Alnylam Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 02043Q107

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site